Immune checkpoint blockade in human cancer therapy: Lung cancer and hematologic malignancies

Murali Janakiram, Vipul Pareek, Haiying Cheng, Deepa M. Narasimhulu, Xingxing Zang

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy. Even though only a small proportion of patients respond to checkpoint blockade, the duration of such responders due to immunological memory is remarkable and is longer than would be expected with any other agent in refractory disease. In this article, we review the therapeutic trials of blocking these pathways in human lung cancer and hematological malignancies.

Original languageEnglish (US)
Pages (from-to)809-819
Number of pages11
JournalImmunotherapy
Volume8
Issue number7
DOIs
StatePublished - Jun 1 2016

Fingerprint

Tumor Escape
Hematologic Neoplasms
Lung Neoplasms
Immunologic Memory
Blocking Antibodies
Poisons
Neoplasms
T-Lymphocytes
Drug Therapy
Therapeutics

Keywords

  • CTLA-4
  • Hodgkin lymphoma
  • immune checkpoint inhibitor
  • immunotherapy
  • leukemia
  • multiple myeloma
  • non-lymphoma
  • non-small-cell lung cancer
  • PD-1
  • PD-L1
  • squamous cell lung cancer

ASJC Scopus subject areas

  • Immunology and Allergy
  • Oncology
  • Immunology

Cite this

Immune checkpoint blockade in human cancer therapy : Lung cancer and hematologic malignancies. / Janakiram, Murali; Pareek, Vipul; Cheng, Haiying; Narasimhulu, Deepa M.; Zang, Xingxing.

In: Immunotherapy, Vol. 8, No. 7, 01.06.2016, p. 809-819.

Research output: Contribution to journalReview article

Janakiram, Murali ; Pareek, Vipul ; Cheng, Haiying ; Narasimhulu, Deepa M. ; Zang, Xingxing. / Immune checkpoint blockade in human cancer therapy : Lung cancer and hematologic malignancies. In: Immunotherapy. 2016 ; Vol. 8, No. 7. pp. 809-819.
@article{0000c25edd0c470c98652d459aca2769,
title = "Immune checkpoint blockade in human cancer therapy: Lung cancer and hematologic malignancies",
abstract = "Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy. Even though only a small proportion of patients respond to checkpoint blockade, the duration of such responders due to immunological memory is remarkable and is longer than would be expected with any other agent in refractory disease. In this article, we review the therapeutic trials of blocking these pathways in human lung cancer and hematological malignancies.",
keywords = "CTLA-4, Hodgkin lymphoma, immune checkpoint inhibitor, immunotherapy, leukemia, multiple myeloma, non-lymphoma, non-small-cell lung cancer, PD-1, PD-L1, squamous cell lung cancer",
author = "Murali Janakiram and Vipul Pareek and Haiying Cheng and Narasimhulu, {Deepa M.} and Xingxing Zang",
year = "2016",
month = "6",
day = "1",
doi = "10.2217/imt-2016-0001",
language = "English (US)",
volume = "8",
pages = "809--819",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "7",

}

TY - JOUR

T1 - Immune checkpoint blockade in human cancer therapy

T2 - Lung cancer and hematologic malignancies

AU - Janakiram, Murali

AU - Pareek, Vipul

AU - Cheng, Haiying

AU - Narasimhulu, Deepa M.

AU - Zang, Xingxing

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy. Even though only a small proportion of patients respond to checkpoint blockade, the duration of such responders due to immunological memory is remarkable and is longer than would be expected with any other agent in refractory disease. In this article, we review the therapeutic trials of blocking these pathways in human lung cancer and hematological malignancies.

AB - Tumor immune evasion is one of the hallmarks of cancer, and expression of the B7 family of immune checkpoints (PD-L1, PD-L2, B7-H3, B7x and HHLA2) is one mechanism of immune evasion by tumors to suppress T-cell function. Antibodies blocking these interactions of B7-1/B7-2/CTLA-4 and PD-L1/PD-L2/PD-1 have had remarkable clinical success in several cancers and are less toxic than traditional chemotherapy. Even though only a small proportion of patients respond to checkpoint blockade, the duration of such responders due to immunological memory is remarkable and is longer than would be expected with any other agent in refractory disease. In this article, we review the therapeutic trials of blocking these pathways in human lung cancer and hematological malignancies.

KW - CTLA-4

KW - Hodgkin lymphoma

KW - immune checkpoint inhibitor

KW - immunotherapy

KW - leukemia

KW - multiple myeloma

KW - non-lymphoma

KW - non-small-cell lung cancer

KW - PD-1

KW - PD-L1

KW - squamous cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=84976908758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84976908758&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0001

DO - 10.2217/imt-2016-0001

M3 - Review article

C2 - 27349980

AN - SCOPUS:84976908758

VL - 8

SP - 809

EP - 819

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 7

ER -